,127 Cenicriviroc (CVC), a dual inhibitor of Ccr2/5, had its phase 3 clinical trials in treating NASH terminated early due to lack of efficacy (NCT03028740).128. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.